Publication Name	World Journal of Clinical Urology
Manuscript ID	25628
Country	United States

Received	2016-03-17 09:44
Peer-Review Started	2016-03-19 15:18
To Make the First Decision	2016-05-17 13:48
Return for Revision	2016-05-19 10:36
Revised	2016-05-26 05:27
Second Decision	2016-06-29 11:27
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-07-13 14:03
Articles in Press	2016-07-13 14:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-22 15:31
Publish the Manuscript Online	2016-07-24 22:27

ISSN	2219-2816 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Editorial
Article Title	Efficacy and safety of onabotulinum toxin A for overactive bladder
Manuscript Source	Invited Manuscript
All Author List	Chintan K Patel and Arthur P Mourtzinos
Funding Agency and Grant Number
Corresponding Author	Chintan K Patel, MD, Resident in Urology, Institute of Urology, Lahey Hospital and Medical Center, 41 Burlington Mall Rd., Burlington, MA 01805, United States. chintan.patel@lahey.org
Key Words	Onabotulinum toxin A; Botox; Overactive bladder; Overactive bladder; Neurogenic bladder; Urinary bladder; Detrusor overactivity
Core Tip	Overactive bladder (OAB) remains a highly prevalent and frequently, a recalcitrant constellation of symptoms. For patients who are refractory to oral medical therapy, there is sufficient level I evidence to support the use of onabotulinum toxin A injection therapy. It is a safe and very effective 2nd line treatment for OAB, even in the elderly population. The suggested Food and Drug Administration approved dose is 100 U to maximize the benefits and minimize the adverse effects of this therapy. Risks of the intradetrusor injection of onabotulinum toxin A include urinary tract infection, increased post void residual, urinary retention which may lead to necessity of self catherization for a period of time.
Publish Date	2016-07-24 22:27
Citation	Patel CK, Mourtzinos AP. Efficacy and safety of onabotulinum toxin A for overactive bladder. World J Clin Urol 2016; 5(2): 75-79
URL	http://www.wjgnet.com/2219-2816/full/v5/i2/75.htm
DOI	http://dx.doi.org/10.5410/wjcu.v5.i2.75

Full Article (PDF)	WJCU-5-75.pdf
Full Article (Word)	WJCU-5-75.doc
Manuscript File	25628-Review.docx
Answering Reviewers	25628-Answering reviewers.pdf
Audio Core Tip	25628-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25628-Conflict-of-interest statement.pdf
Copyright License Agreement	25628-Copyright assignment.pdf
Peer-review Report	25628-Peer-review(s).pdf
Scientific Misconduct Check	25628-Scientific misconduct check.pdf
Scientific Editor Work List	25628-Scientific editor work list.pdf